Delving into the Latest Updates on Aulimanid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism

Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pulmonary Tuberculosis

Inactive Indication-

Originator Organization

Nanjing Changao Pharmaceutical Science & Technology Co. Ltd.

Active Organization

Nanjing Changao Pharmaceutical Science & Technology Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

RegulationSpecial Review Project (CN)

Login to view timeline

主要目的：评价中国健康受试者空腹单次口服YF-49-92.MLS的安全性及耐受性。次要目的：评价中国健康受试者空腹单次口服YF-49-92.MLS的药代动力学特征。评价食物对中国健康受试者单次口服YF-49-92.MLS的药代动力学和安全性的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single oral fasting dose of YF-49-92.MLS in healthy Chinese subjects. Secondary objective: To evaluate the pharmacokinetic characteristics of a single oral fasting dose of YF-49-92.MLS in healthy Chinese subjects. To evaluate the effect of food on the pharmacokinetics and safety of a single oral fasting dose of YF-49-92.MLS in healthy Chinese subjects.

Start Date16 Oct 2019

Sponsor / Collaborator

Nanjing Changao Pharmaceutical Science & Technology Co. Ltd.

[+1]

100 Clinical Results associated with Aulimanid

Login to view more data

100 Translational Medicine associated with Aulimanid

Login to view more data

100 Patents (Medical) associated with Aulimanid

Login to view more data

100 Deals associated with Aulimanid

Login to view more data